Alterations in the expression levels of the regulators of programmed cell death, the Bcl-2 family proteins are common in hematologic malignancies [38] which may explain the variation in the rIT-enhancing effects of paclitaxel in vitro [37]. The gene discussed is BCL2; the disease is hematologic disorder.